US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NEUROGENE INC

20.35

-1.0600-4.95%

Post-market: 20.350.00000.00%19:07 EDT

Volume:130.61K

Turnover:2.66M

Market Cap:315.22M

PE:-4.80

High:21.32

Open:21.30

Low:19.50

Close:21.41

52wk High:37.27

52wk Low:6.88

Shares:15.49M

Float Shares:6.02M

Volume Ratio:0.66

T/O Rate:2.17%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.2400

EPS(LYR):-4.2400

ROE:-31.41%

ROA:-20.66%

PB:1.19

PE(LYR):-4.80

Loading ...

Overview Company News Filings

Stifel Nicolaus Keeps Their Buy Rating on Neurogene (NGNE)

BUZZ-Neurogene jumps after FDA's breakthrough tag for neurological disorder therapy

Neurogene Shares Jump 32% Premarket on FDA's 'Breakthrough Therapy' Tag for Neurological Disorder Therapy

THOMSON REUTERS

Neurogene initiated with a Buy at Canaccord

Neurogene jumps 36% to $26.71 after Canaccord puts $200 target on shares

FDA Grants Breakthrough Therapy Designation to Neurogene's NGN-401 for Rett Syndrome

Neurogene Announces FDA Breakthrough Therapy Designation for Ngn-401 Gene Therapy for Rett Syndrome

THOMSON REUTERS

Neurogene Inc - Dosing in Embolden Trial to Complete by Q2 2026

THOMSON REUTERS

Neurogene Inc - Additional Phase 1/2 Data to Be Presented Mid-2026

THOMSON REUTERS

Neurogene Inc. nimmt an wichtigen Investorenkonferenzen teil

BRIEF-Neurogene Announces Inducement Grant Under Nasdaq Listing Rule

Neurogene Grants Stock Options to New Employee Under Inducement Plan

Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

Neurogene Initiated at Outperform by LifeSci Capital

Neurogene initiated with an Outperform at LifeSci Capital

Neurogene Price Target Maintained With a $70.00/Share by HC Wainwright & Co.

Neurogene (NGNE) Gets a Buy from H.C. Wainwright

Neurogene Showcases Rett Syndrome Gene Therapy Progress at J.P. Morgan Healthcare Conference

Neurogene Advances NGN-401 Gene Therapy for Rett Syndrome with Embolden Trial Dosing and Upcoming 2026 Milestones

Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for Ngn-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NGNE/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NGNE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NGNE\",,,,,undefined,":{"symbol":"NGNE","market":"US","secType":"STK","nameCN":"NEUROGENE INC","latestPrice":20.35,"timestamp":1774641600000,"preClose":21.41,"halted":0,"volume":130611,"hourTrading":{"tag":"盘后","latestPrice":20.35,"preClose":20.35,"latestTime":"19:07 EDT","volume":537,"amount":10931.35,"timestamp":1774652844874,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.04950957496496958,"floatShares":6017500,"shares":15489800,"eps":-4.24,"marketStatus":"Market Closed","change":-1.06,"latestTime":"03-27 16:00:00 EDT","open":21.3,"high":21.32,"low":19.5,"amount":2657467.3075079997,"amplitude":0.085007,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.24,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"listingDate":1394168400000,"exchange":"NASDAQ","adjPreClose":21.41,"preHourTrading":{"tag":"盘前","latestPrice":21.5,"preClose":21.41,"latestTime":"09:29 EDT","volume":6500,"amount":143317.26499999998,"timestamp":1774618199099,"change":0.09,"changeRate":0.004204,"amplitude":0.055582},"postHourTrading":{"tag":"盘后","latestPrice":20.35,"preClose":20.35,"latestTime":"19:07 EDT","volume":537,"amount":10931.35,"timestamp":1774652844874,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.663279,"impliedVol":0.8345,"impliedVolPercentile":0.2311},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NGNE\",,,,,undefined,":{"symbol":"NGNE","floatShares":6017500,"roa":"-20.66%","roe":"-31.41%","lyrEps":-4.24,"volumeRatio":0.663279,"shares":15489800,"dividePrice":0,"high":21.32,"amplitude":0.085007,"preClose":21.41,"low":19.5,"week52Low":6.875,"pbRate":"1.19","week52High":37.2659,"institutionHeld":0,"latestPrice":20.35,"eps":-4.24,"divideRate":0,"volume":130611,"delay":0,"ttmEps":-4.24,"open":21.3,"prevYearClose":20.6,"prevWeekClose":19.05,"prevMonthClose":23.49,"prevQuarterClose":20.6,"fiveDayClose":19.05,"twentyDayClose":23.49,"sixtyDayClose":22.11},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NGNE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-24","symbol":"NGNE","fiscalQuarterEnding":"2025/12","expectedEps":-1.2,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1774324800000,"reportTimeType":"pre","actualEps":-1.12},{"market":"US","date":"2025-11-13","symbol":"NGNE","fiscalQuarterEnding":"2025/09","expectedEps":-1.26,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.99},{"market":"US","date":"2025-08-11","symbol":"NGNE","fiscalQuarterEnding":"2025/06","expectedEps":-1.15,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754884800000,"reportTimeType":"post","actualEps":-1.05},{"market":"US","date":"2025-05-09","symbol":"NGNE","fiscalQuarterEnding":"2025/03","expectedEps":-1.05,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746763200000,"reportTimeType":"pre","actualEps":-1.08},{"market":"US","date":"2025-03-24","symbol":"NGNE","fiscalQuarterEnding":"2024/12","expectedEps":-1.04,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742788800000,"reportTimeType":"post","actualEps":-0.99}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NGNE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NGNE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.375,"buy":0.625,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.625,"analysts":8,"updateTime":1772251200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NGNE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NGNE","date":"2026-03-27","current":-4.799528,"percent":0.700368,"low":-19.523035,"twenty":-10.698793,"median":-4.862014,"eighty":-3.371873,"high":-1.458307,"avg":-6.651786,"sd":3.948564,"marketCap":333445613},"quantilePoints":[{"date":"2023-12-29","current":-4.323556,"twenty":-4.185645,"median":-3.978778,"eighty":-3.916869,"marketCap":220311097},{"date":"2024-01-05","current":-5.423319,"twenty":-5.000527,"median":-4.624292,"eighty":-3.978778,"marketCap":276350648},{"date":"2024-01-12","current":-8.005373,"twenty":-7.157271,"median":-5.423319,"eighty":-4.323556,"marketCap":407921769},{"date":"2024-01-19","current":-7.59768,"twenty":-7.599292,"median":-7.086806,"eighty":-4.804734,"marketCap":387147382},{"date":"2024-01-26","current":-8.053188,"twenty":-7.611677,"median":-7.561189,"eighty":-4.985427,"marketCap":410358272},{"date":"2024-02-02","current":-7.741127,"twenty":-7.937424,"median":-7.577547,"eighty":-5.338761,"marketCap":394456888},{"date":"2024-02-09","current":-7.497015,"twenty":-7.980207,"median":-7.59013,"eighty":-6.388695,"marketCap":382017903},{"date":"2024-02-16","current":-7.549864,"twenty":-7.937424,"median":-7.577547,"eighty":-6.995453,"marketCap":384710880},{"date":"2024-02-23","current":-7.622846,"twenty":-7.894138,"median":-7.57503,"eighty":-7.129085,"marketCap":388429751},{"date":"2024-03-01","current":-7.819143,"twenty":-7.894138,"median":-7.588872,"eighty":-7.262969,"marketCap":398432234},{"date":"2024-03-08","current":-9.734292,"twenty":-8.024499,"median":-7.59768,"eighty":-7.381754,"marketCap":496020561},{"date":"2024-03-15","current":-8.697444,"twenty":-8.083388,"median":-7.629138,"eighty":-7.463796,"marketCap":443186933},{"date":"2024-03-22","current":-17.419498,"twenty":-9.10262,"median":-7.660596,"eighty":-7.498525,"marketCap":632623921},{"date":"2024-03-28","current":-17.433655,"twenty":-9.373408,"median":-7.741127,"eighty":-7.499532,"marketCap":633138041},{"date":"2024-04-05","current":-15.090764,"twenty":-9.721205,"median":-7.845567,"eighty":-7.510605,"marketCap":548051280},{"date":"2024-04-12","current":-13.565408,"twenty":-14.180505,"median":-7.97769,"eighty":-7.536275,"marketCap":492654915},{"date":"2024-04-19","current":-11.176509,"twenty":-13.912948,"median":-8.029281,"eighty":-7.549864,"marketCap":405897266},{"date":"2024-04-26","current":-10.571321,"twenty":-13.650346,"median":-8.053188,"eighty":-7.549864,"marketCap":383918661},{"date":"2024-05-03","current":-12.537284,"twenty":-13.442874,"median":-8.146303,"eighty":-7.558924,"marketCap":455316556},{"date":"2024-05-10","current":-11.764996,"twenty":-13.2542,"median":-9.074937,"eighty":-7.57352,"marketCap":427269365},{"date":"2024-05-17","current":-10.587696,"twenty":-13.13876,"median":-9.272492,"eighty":-7.576037,"marketCap":433830864},{"date":"2024-05-24","current":-9.887502,"twenty":-12.800854,"median":-9.44488,"eighty":-7.581574,"marketCap":405140389},{"date":"2024-05-31","current":-10.685033,"twenty":-12.52136,"median":-9.620612,"eighty":-7.588117,"marketCap":437819226},{"date":"2024-06-07","current":-11.771752,"twenty":-12.409114,"median":-9.810897,"eighty":-7.59013,"marketCap":482347539},{"date":"2024-06-14","current":-13.301826,"twenty":-12.457666,"median":-9.93146,"eighty":-7.59013,"marketCap":545042335},{"date":"2024-06-21","current":-9.842528,"twenty":-12.564112,"median":-9.93146,"eighty":-7.59617,"marketCap":403297579},{"date":"2024-06-28","current":-11.030474,"twenty":-12.52136,"median":-10.019377,"eighty":-7.599292,"marketCap":451973662},{"date":"2024-07-05","current":-11.397945,"twenty":-12.537284,"median":-10.188931,"eighty":-7.605739,"marketCap":467030798},{"date":"2024-07-12","current":-13.232134,"twenty":-12.537284,"median":-10.458961,"eighty":-7.622846,"marketCap":542186671},{"date":"2024-07-15","current":-13.48873,"twenty":-12.644595,"median":-10.463671,"eighty":-7.625363,"marketCap":552700705},{"date":"2024-08-02","current":-12.832984,"twenty":-12.76836,"median":-10.468381,"eighty":-7.627879,"marketCap":525831507},{"date":"2024-08-09","current":-11.578513,"twenty":-12.617767,"median":-10.579508,"eighty":-7.644992,"marketCap":474429562},{"date":"2024-08-16","current":-9.721942,"twenty":-12.533918,"median":-10.468381,"eighty":-7.659841,"marketCap":462832495},{"date":"2024-08-23","current":-9.22793,"twenty":-12.500388,"median":-10.20777,"eighty":-7.686769,"marketCap":439314055},{"date":"2024-08-30","current":-9.934831,"twenty":-12.3607,"median":-10.082175,"eighty":-7.732068,"marketCap":472967513},{"date":"2024-09-06","current":-9.383503,"twenty":-12.215183,"median":-10.030358,"eighty":-7.751697,"marketCap":446720414},{"date":"2024-09-13","current":-11.015654,"twenty":-12.198503,"median":-10.056266,"eighty":-7.799009,"marketCap":524422220},{"date":"2024-09-20","current":-11.343175,"twenty":-12.111032,"median":-10.20463,"eighty":-7.829713,"marketCap":540014556},{"date":"2024-09-27","current":-10.69359,"twenty":-12.018852,"median":-10.282823,"eighty":-7.883065,"marketCap":509089757},{"date":"2024-10-04","current":-12.12104,"twenty":-12.018852,"median":-10.468381,"eighty":-7.937424,"marketCap":577046353},{"date":"2024-10-11","current":-13.141817,"twenty":-12.215183,"median":-10.579508,"eighty":-7.980207,"marketCap":625642465},{"date":"2024-10-18","current":-14.443716,"twenty":-12.644595,"median":-10.678753,"eighty":-7.993293,"marketCap":687621999},{"date":"2024-10-25","current":-13.155463,"twenty":-12.975228,"median":-10.69616,"eighty":-8.014936,"marketCap":626292146},{"date":"2024-10-31","current":-11.938174,"twenty":-12.976568,"median":-10.764003,"eighty":-8.053188,"marketCap":568340632},{"date":"2024-11-08","current":-18.968977,"twenty":-13.201862,"median":-10.833215,"eighty":-8.053188,"marketCap":903056103},{"date":"2024-11-15","current":-10.699049,"twenty":-13.232134,"median":-10.867118,"eighty":-8.053188,"marketCap":509349629},{"date":"2024-11-22","current":-3.804354,"twenty":-13.201862,"median":-10.811892,"eighty":-8.005373,"marketCap":202570426},{"date":"2024-11-29","current":-7.081932,"twenty":-13.164743,"median":-10.73726,"eighty":-7.916284,"marketCap":377091628},{"date":"2024-12-06","current":-6.123936,"twenty":-13.144546,"median":-10.69616,"eighty":-7.738107,"marketCap":326081199},{"date":"2024-12-13","current":-6.220014,"twenty":-13.009618,"median":-10.678753,"eighty":-7.632912,"marketCap":331197071},{"date":"2024-12-20","current":-6.147607,"twenty":-12.971208,"median":-10.579508,"eighty":-7.59013,"marketCap":327341631},{"date":"2024-12-27","current":-6.711544,"twenty":-12.908645,"median":-10.50763,"eighty":-7.57654,"marketCap":357369573},{"date":"2025-01-03","current":-6.374574,"twenty":-12.853892,"median":-10.405691,"eighty":-7.549864,"marketCap":339426951},{"date":"2025-01-10","current":-5.995231,"twenty":-12.800672,"median":-10.212067,"eighty":-7.505069,"marketCap":319228040},{"date":"2025-01-17","current":-4.918377,"twenty":-12.651961,"median":-10.173232,"eighty":-7.427764,"marketCap":261888801},{"date":"2025-01-24","current":-4.346472,"twenty":-12.574112,"median":-10.030358,"eighty":-7.086806,"marketCap":231436615},{"date":"2025-01-31","current":-4.332524,"twenty":-12.537284,"median":-9.920586,"eighty":-6.842433,"marketCap":230693879},{"date":"2025-02-07","current":-6.50018,"twenty":-12.535901,"median":-9.842528,"eighty":-6.605719,"marketCap":346115092},{"date":"2025-02-14","current":-5.236411,"twenty":-12.52887,"median":-9.777894,"eighty":-6.491539,"marketCap":278823188},{"date":"2025-02-21","current":-4.829104,"twenty":-12.471907,"median":-9.750601,"eighty":-6.430271,"marketCap":257135289},{"date":"2025-02-28","current":-4.770518,"twenty":-12.349943,"median":-9.721942,"eighty":-6.303838,"marketCap":254015797},{"date":"2025-03-07","current":-4.672876,"twenty":-12.236804,"median":-9.661093,"eighty":-6.2189,"marketCap":248816643},{"date":"2025-03-14","current":-4.686825,"twenty":-12.214976,"median":-9.588204,"eighty":-6.130619,"marketCap":249559380},{"date":"2025-03-21","current":-4.24883,"twenty":-12.149292,"median":-9.555425,"eighty":-6.004158,"marketCap":226237461},{"date":"2025-03-28","current":-3.045755,"twenty":-12.12341,"median":-9.468113,"eighty":-5.45457,"marketCap":228870246},{"date":"2025-04-04","current":-1.92123,"twenty":-12.043093,"median":-9.418302,"eighty":-5.225252,"marketCap":144368903},{"date":"2025-04-11","current":-1.782154,"twenty":-12.004592,"median":-9.374415,"eighty":-5.034123,"marketCap":133918207},{"date":"2025-04-17","current":-2.044108,"twenty":-11.997937,"median":-9.328916,"eighty":-4.961897,"marketCap":153602450},{"date":"2025-04-25","current":-2.917172,"twenty":-11.976697,"median":-9.167755,"eighty":-4.922368,"marketCap":219207954},{"date":"2025-05-02","current":-2.922866,"twenty":-11.956745,"median":-9.074937,"eighty":-4.83359,"marketCap":219635816},{"date":"2025-05-09","current":-2.846947,"twenty":-11.943832,"median":-8.430682,"eighty":-4.764939,"marketCap":213930990},{"date":"2025-05-16","current":-3.416053,"twenty":-11.921952,"median":-8.053188,"eighty":-4.703006,"marketCap":276256218},{"date":"2025-05-23","current":-3.181497,"twenty":-11.907794,"median":-8.053188,"eighty":-4.667296,"marketCap":257287670},{"date":"2025-05-30","current":-3.304948,"twenty":-11.891321,"median":-7.997823,"eighty":-4.63103,"marketCap":267271116},{"date":"2025-06-06","current":-4.042124,"twenty":-11.854896,"median":-7.927357,"eighty":-4.432955,"marketCap":326886552},{"date":"2025-06-13","current":-3.597702,"twenty":-11.83216,"median":-7.80656,"eighty":-4.329176,"marketCap":290946146},{"date":"2025-06-20","current":-3.22735,"twenty":-11.824338,"median":-7.733577,"eighty":-4.305184,"marketCap":260995807},{"date":"2025-06-27","current":-2.922251,"twenty":-11.790759,"median":-7.659337,"eighty":-4.202034,"marketCap":236322433},{"date":"2025-07-03","current":-3.543031,"twenty":-11.778088,"median":-7.622846,"eighty":-3.964273,"marketCap":286524905},{"date":"2025-07-11","current":-3.87282,"twenty":-11.778088,"median":-7.593905,"eighty":-3.821676,"marketCap":313194969},{"date":"2025-07-18","current":-3.985689,"twenty":-11.771752,"median":-7.587614,"eighty":-3.805804,"marketCap":322322691},{"date":"2025-07-25","current":-4.022724,"twenty":-11.764996,"median":-7.573772,"eighty":-3.819913,"marketCap":325317725},{"date":"2025-08-01","current":-3.839312,"twenty":-11.670697,"median":-7.549864,"eighty":-3.819913,"marketCap":310485176},{"date":"2025-08-08","current":-3.784641,"twenty":-11.657709,"median":-7.513374,"eighty":-3.804354,"marketCap":306063936},{"date":"2025-08-15","current":-3.416033,"twenty":-11.655175,"median":-7.497015,"eighty":-3.77935,"marketCap":288292703},{"date":"2025-08-22","current":-3.339933,"twenty":-11.654541,"median":-7.373701,"eighty":-3.740907,"marketCap":281870341},{"date":"2025-08-29","current":-3.186043,"twenty":-11.623292,"median":-7.086806,"eighty":-3.597702,"marketCap":268882897},{"date":"2025-09-05","current":-3.316258,"twenty":-11.587469,"median":-7.081932,"eighty":-3.564545,"marketCap":279872272},{"date":"2025-09-12","current":-3.39574,"twenty":-11.537964,"median":-6.776988,"eighty":-3.481558,"marketCap":286580073},{"date":"2025-09-19","current":-3.158985,"twenty":-11.502485,"median":-6.605719,"eighty":-3.434395,"marketCap":266599390},{"date":"2025-09-26","current":-2.943369,"twenty":-11.461109,"median":-6.573692,"eighty":-3.385336,"marketCap":248402697},{"date":"2025-10-03","current":-3.547939,"twenty":-11.450166,"median":-6.491539,"eighty":-3.377814,"marketCap":299424797},{"date":"2025-10-10","current":-5.337129,"twenty":-11.445253,"median":-6.449765,"eighty":-3.380182,"marketCap":450421668},{"date":"2025-10-17","current":-5.748068,"twenty":-11.407188,"median":-6.374574,"eighty":-3.383551,"marketCap":485102424},{"date":"2025-10-24","current":-4.855164,"twenty":-11.397945,"median":-6.302167,"eighty":-3.385336,"marketCap":409746708},{"date":"2025-10-31","current":-5.604324,"twenty":-11.395615,"median":-6.221406,"eighty":-3.393711,"marketCap":472971296},{"date":"2025-11-07","current":-4.508487,"twenty":-11.353547,"median":-6.20957,"eighty":-3.411974,"marketCap":380489280},{"date":"2025-11-14","current":-4.862014,"twenty":-11.286405,"median":-6.13229,"eighty":-3.416049,"marketCap":410324802},{"date":"2025-11-21","current":-3.711875,"twenty":-11.19565,"median":-6.083345,"eighty":-3.434395,"marketCap":315991920},{"date":"2025-11-28","current":-3.835604,"twenty":-11.143862,"median":-6.000811,"eighty":-3.441096,"marketCap":326524984},{"date":"2025-12-05","current":-3.850161,"twenty":-11.110635,"median":-5.793728,"eighty":-3.451989,"marketCap":327764168},{"date":"2025-12-12","current":-3.868356,"twenty":-11.06004,"median":-5.680588,"eighty":-3.464399,"marketCap":329313148},{"date":"2025-12-19","current":-3.508086,"twenty":-11.030846,"median":-5.604324,"eighty":-3.47695,"marketCap":298643344},{"date":"2025-12-26","current":-3.65183,"twenty":-11.024546,"median":-5.462383,"eighty":-3.4835,"marketCap":310880286},{"date":"2026-01-02","current":-3.748266,"twenty":-11.014016,"median":-5.423319,"eighty":-3.488028,"marketCap":319089880},{"date":"2026-01-09","current":-3.398913,"twenty":-11.004191,"median":-5.362496,"eighty":-3.47056,"marketCap":289349464},{"date":"2026-01-16","current":-3.286101,"twenty":-10.982901,"median":-5.337129,"eighty":-3.424394,"marketCap":279745788},{"date":"2026-01-23","current":-3.455319,"twenty":-10.950149,"median":-5.255956,"eighty":-3.416033,"marketCap":294151302},{"date":"2026-01-30","current":-3.437123,"twenty":-10.917397,"median":-5.24669,"eighty":-3.416033,"marketCap":292602322},{"date":"2026-02-06","current":-2.978598,"twenty":-10.901021,"median":-5.220443,"eighty":-3.384309,"marketCap":253568026},{"date":"2026-02-13","current":-3.093229,"twenty":-10.833215,"median":-5.176431,"eighty":-3.360227,"marketCap":263326600},{"date":"2026-02-20","current":-3.387996,"twenty":-10.826322,"median":-5.1238,"eighty":-3.344395,"marketCap":288420076},{"date":"2026-02-27","current":-3.580868,"twenty":-10.814433,"median":-5.042522,"eighty":-3.344395,"marketCap":304839264},{"date":"2026-03-06","current":-4.026657,"twenty":-10.794975,"median":-4.976962,"eighty":-3.351841,"marketCap":342789274},{"date":"2026-03-13","current":-4.057589,"twenty":-10.747957,"median":-4.935115,"eighty":-3.358866,"marketCap":345422540},{"date":"2026-03-20","current":-3.49171,"twenty":-10.706691,"median":-4.921703,"eighty":-3.363519,"marketCap":297249262},{"date":"2026-03-27","current":-3.690558,"twenty":-10.698793,"median":-4.862014,"eighty":-3.371873,"marketCap":333445613}],"updateTime":1774740623845},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NGNE\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2614885256","title":"Stifel Nicolaus Keeps Their Buy Rating on Neurogene (NGNE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614885256","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614885256?lang=en_us&edition=fundamental","pubTime":"2026-02-27 22:35","pubTimestamp":1772202921,"startTime":"0","endTime":"0","summary":"In a report released today, Paul Matteis from Stifel Nicolaus reiterated a Buy rating on Neurogene, with a price target of $46.00. Matteis covers t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-neurogene-ngne-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-neurogene-ngne-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","NGNE"],"gpt_icon":0},{"id":"2614830447","title":"BUZZ-Neurogene jumps after FDA's breakthrough tag for neurological disorder therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2614830447","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614830447?lang=en_us&edition=fundamental","pubTime":"2026-02-27 19:56","pubTimestamp":1772193362,"startTime":"0","endTime":"0","summary":"BUZZ-Neurogene jumps after FDA's breakthrough tag for neurological disorder therapy ** Shares of drug developer Neurogene NGNE.O rise about 28% to $25.13 premarket** Co says the U.S. FDA granted breakthrough therapy status to its experimental gene therapy, NGN-401, for a rare neurological disorder ** The breakthrough tag is meant to speed up development and review of drugs to treat a serious condition or unmet medical need** NGN-401 is being tested as a one-time treatment for Rett syndrome, a rare disorder starting in infancy, causing loss of speech and movement, seizures and breathing problems ** Co says FDA decision was based on interim early-stage trial data showing meaningful, lasting improvements across multiple areas of daily function** Expects to complete dosing in its registrational study in Q2 2026; plans to release additional interim data in mid-2026** NGNE shares were down over 9% in 2025   ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nL4N3ZN0SM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2614837381","title":"Neurogene Shares Jump 32% Premarket on FDA's 'Breakthrough Therapy' Tag for Neurological Disorder Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2614837381","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614837381?lang=en_us&edition=fundamental","pubTime":"2026-02-27 19:18","pubTimestamp":1772191082,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nFWN3ZN12G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2614832972","title":"Neurogene initiated with a Buy at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2614832972","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614832972?lang=en_us&edition=fundamental","pubTime":"2026-02-27 18:50","pubTimestamp":1772189455,"startTime":"0","endTime":"0","summary":"Canaccord analyst Whitney Ijem initiated coverage of Neurogene (NGNE) with a Buy rating and $200 price target Published first on TheFly – the ultim...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurogene-initiated-with-a-buy-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurogene-initiated-with-a-buy-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2614832940","title":"Neurogene jumps 36% to $26.71 after Canaccord puts $200 target on shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2614832940","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614832940?lang=en_us&edition=fundamental","pubTime":"2026-02-27 18:50","pubTimestamp":1772189414,"startTime":"0","endTime":"0","summary":"05:49 EST Neurogene (NGNE) jumps 36% to $26.71 after Canaccord puts $200 target on shares Published first on TheFly – the ultimate source for real-...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurogene-jumps-36-to-26-71-after-canaccord-puts-200-target-on-shares-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurogene-jumps-36-to-26-71-after-canaccord-puts-200-target-on-shares-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2614075629","title":"FDA Grants Breakthrough Therapy Designation to Neurogene's NGN-401 for Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2614075629","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614075629?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:02","pubTimestamp":1772139741,"startTime":"0","endTime":"0","summary":"Neurogene Inc. said the U.S. Food and Drug Administration granted Breakthrough Therapy designation to NGN-401, its investigational gene therapy for Rett syndrome. The designation was based on interim Phase 1/2 efficacy and safety data as of Oct. 30, 2025, and NGN-401 is currently being evaluated in the Embolden registrational trial, with dosing expected to be completed in the second quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurogene Inc. published the original content used to generate this news brief via Business Wire  on February 26, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL7QDKTw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2614393075","title":"Neurogene Announces FDA Breakthrough Therapy Designation for Ngn-401 Gene Therapy for Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2614393075","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614393075?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:01","pubTimestamp":1772139661,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUA35NBQZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2614075515","title":"Neurogene Inc - Dosing in Embolden Trial to Complete by Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2614075515","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614075515?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:01","pubTimestamp":1772139661,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUA35NBQZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2614075354","title":"Neurogene Inc - Additional Phase 1/2 Data to Be Presented Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2614075354","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614075354?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:01","pubTimestamp":1772139661,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUA35NBQZ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2609949377","title":"Neurogene Inc. nimmt an wichtigen Investorenkonferenzen teil","url":"https://stock-news.laohu8.com/highlight/detail?id=2609949377","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609949377?lang=en_us&edition=fundamental","pubTime":"2026-02-05 20:30","pubTimestamp":1770294643,"startTime":"0","endTime":"0","summary":"Neurogene Inc. wird am Donnerstag, den 12. Februar, am Guggenheim Emerging Outlook: Biotech Summit 2026 teilnehmen. Das Unternehmen nimmt ebenfalls am Mittwoch, den 4. Mrz, an der TD Cowen 46th Annual Health Care Conference und am Montag, den 9. Mrz, an der Leerink Global Healthcare Conference teil.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurogene Inc. published the original content used to generate this news brief via Business Wire  on February 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL3tTKXC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2609318812","title":"BRIEF-Neurogene Announces Inducement Grant Under Nasdaq Listing Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2609318812","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609318812?lang=en_us&edition=fundamental","pubTime":"2026-02-05 05:01","pubTimestamp":1770238908,"startTime":"0","endTime":"0","summary":"BRIEF-Neurogene Announces Inducement Grant Under Nasdaq Listing RuleFeb 4 (Reuters) - Neurogene Inc NGNE.O:NEUROGENE ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)Source text: ID:nBwNpwGfaFurther company coverage: NGNE.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nTUA5GYZMJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2609318332","title":"Neurogene Grants Stock Options to New Employee Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2609318332","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609318332?lang=en_us&edition=fundamental","pubTime":"2026-02-05 05:01","pubTimestamp":1770238873,"startTime":"0","endTime":"0","summary":"Neurogene Inc. has approved a grant of non-qualified stock options to purchase 2,820 shares of the company’s common stock for a new employee, with the options granted under the company’s 2025 Inducement Plan. The options have an exercise price equal to the closing price of Neurogene’s common stock on the grant date of February 2, 2026. Vesting will occur over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal monthly installments over the following three years, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurogene Inc. published the original content used to generate this news brief via Business Wire  on February 04, 2026","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL17ClRs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2609907093","title":"Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2609907093","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609907093?lang=en_us&edition=fundamental","pubTime":"2026-02-05 05:01","pubTimestamp":1770238860,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nTUA5GYZMJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2606455122","title":"Neurogene Initiated at Outperform by LifeSci Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2606455122","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606455122?lang=en_us&edition=fundamental","pubTime":"2026-01-26 21:55","pubTimestamp":1769435700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NGNE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 26, 2026 08:55 ET (13:55 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2606248600","title":"Neurogene initiated with an Outperform at LifeSci Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2606248600","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606248600?lang=en_us&edition=fundamental","pubTime":"2026-01-26 20:55","pubTimestamp":1769432128,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Patrick Dolezal initiated coverage of Neurogene (NGNE) with an Outperform rating and $50 price target Published first on Th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurogene-initiated-with-an-outperform-at-lifesci-capital-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurogene-initiated-with-an-outperform-at-lifesci-capital-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2603068911","title":"Neurogene Price Target Maintained With a $70.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2603068911","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603068911?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:31","pubTimestamp":1768307460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NGNE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 13, 2026 07:31 ET (12:31 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2603853936","title":"Neurogene (NGNE) Gets a Buy from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2603853936","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603853936?lang=en_us&edition=fundamental","pubTime":"2026-01-13 19:36","pubTimestamp":1768304212,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Neurogene today and set a price target of $70.00. According to TipRanks, Kapoor ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/neurogene-ngne-gets-a-buy-from-h-c-wainwright-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/neurogene-ngne-gets-a-buy-from-h-c-wainwright-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2603863542","title":"Neurogene Showcases Rett Syndrome Gene Therapy Progress at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2603863542","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603863542?lang=en_us&edition=fundamental","pubTime":"2026-01-13 00:27","pubTimestamp":1768235271,"startTime":"0","endTime":"0","summary":"Neurogene Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14 at 7:30 a.m. PT. The presentation will be accessible via webcast from the Investor Relations section of Neurogene's website, with a replay available for a limited time.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurogene Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL3VldlY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2602514911","title":"Neurogene Advances NGN-401 Gene Therapy for Rett Syndrome with Embolden Trial Dosing and Upcoming 2026 Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2602514911","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602514911?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:01","pubTimestamp":1768219298,"startTime":"0","endTime":"0","summary":"Neurogene Inc. announced recent progress in its NGN-401 gene therapy program for Rett syndrome. Multiple participants have been dosed in the Embolden registrational trial, with dosing expected to be completed in the second quarter of 2026. The company plans to present interim safety and efficacy data from its Phase 1/2 trial, including at least 12 months of follow-up for all participants in the pediatric and adolescent/adult cohorts, in mid-2026. Early commercial-readiness activities are underway, and Neurogene has reported positive interim data from the Phase 1/2 trial, demonstrating durable multidomain improvements across a spectrum of disease severity. The company is scheduled to present at the J.P. Morgan Healthcare Conference on January 14.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL343X1y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJTD4N35.SGD","LU2211815571.USD","LU2237443622.USD","LU2242649171.HKD","LU2430703251.USD","LU2054465674.USD","IE00BJLML261.HKD","LU0251132253.USD","LU1551013342.USD","LU2237443549.SGD","LU0106261372.USD","IE00BLSP4452.SGD","IE00BKDWB100.SGD","LU1974910355.USD","LU2746668974.SGD","LU0048584097.USD","LU0208291251.USD","LU0345769631.USD","LU2237443895.HKD","NGNE","IE0034235303.USD","BK4566","LU2505996509.AUD","LU0345770993.USD","LU2756315318.SGD","LU2430703095.HKD","LU0310799852.SGD","LU1496350502.SGD","LU1551013425.SGD","LU1261432733.SGD","LU1032466523.USD","IE0034235295.USD","LU0868494617.USD","LU2381873111.SGD","LU0267386448.USD","LU0215105999.USD","LU2417539215.USD","IE00B775SV38.USD","LU0149725797.USD","IE00BWXC8680.SGD","IE00BHPRN162.USD","LU0868494708.USD","LU1720051017.SGD","BK4534","LU0820561909.HKD","IE00BJTD4V19.USD","LU2213496289.HKD","LU0689472784.USD","LU0320765646.SGD","LU2023250330.USD"],"gpt_icon":0},{"id":"2602594514","title":"Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for Ngn-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2602594514","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602594514?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUASZXTG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NGNE"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":72,"code":"91000000","status":"200"}]}}